Series - Raising Capital

The Biotechnology Innovation Organization (BIO) presents this webinar to hear from top Big Pharma professionals in search & evaluation licensing and venture investing about what it takes to get them interested in a new technology. We look at their recent deals and ask why they got done, explore the challenges and learn what makes a technology exciting. Then we dive into a discussion on what tech/modalities and platforms are seen as exciting. Finally, we get advice for those biotechs that are ready for licensing or investment.

The Biotechnology Innovation Organization (BIO) hosts this candid chat with three major investors from our biotechnology community. Gain valuable insights and be ready to ace pitching world-changing solutions in the face of a down-trending market at the 2022 BIO International Convention, June 13-16, in San Diego, California.

For more details visit http://bio.org/convention

Introduction from Mike Liccardo, VP Corporate Development and CFO, ShareVault

A private biotech that announces a definitive agreement with a SPAC jumps into the public investor spotlight and faces that attention with fewer guardrails than the IPO process, plus a need to transform board, investor, and regulatory relations. Given that most SPAC merger deals also involve follow-on PIPE investment rounds or other transactions, the full fundraising benefits of the deal strategy require a smooth de-SPAC process that a private biotech would never have encountered before. View this webinar to learn best practices for navigating from SPAC deal announcement through de-SPAC process to regular life managing a publicly traded company.  

Nearly 30 life science SPAC deals have closed or announced definitive agreements within the past year, helping private companies access new capital and public markets quickly. However, even recent traditions in SPAC deal terms continue to evolve because of statements from regulators regarding the accounting for warrants, shifts in investor expectations, and the availability of PIPE deal supporters, among other factors. View this Biotechnology Innovation Organization (BIO) webinar's discussion of best practices for negotiating SPAC deal terms in today’s market to maximize raising capital to serve biomedical innovation. Learn from the following deal-making experts as they answer audience questions during the session.  

This session is part of the "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.

More than 60 public Special Purpose Acquisition Companies (SPACs) are currently seeking life science companies for merger deals. Join this Biotechnology Innovation Organization (BIO) webinar to learn which financial, scientific, and managerial characteristics are most appealing to SPAC sponsors and the critical factors biotech management teams should prioritize in reviewing SPACs as potential fundraising sources. Learn from the following deal-making experts as they answer the moderator's and the audience's questions during the session.  

This session is part of BIO's "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.